At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
Read More
AAO: Janssen announces late-breaking data from a pair of gene therapy programs
October 2nd 2022In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Read More
Donation bolsters Vanderbilt’s work in retinal vision research
October 1st 2022According to a Vanderbilt University news release, the International Retinal Research Foundation has extended a $10 million gift to establish a center dedicated to retinal vision research at the Vanderbilt Eye Institute and a directorship to support a physician-scientist leader in the Department of Ophthalmology and Visual Sciences.
Read More
ICYMI: Blog offers pearls about the diagnosis, treatment of visual snow syndrome
September 29th 2022On this week's episode of the NeuroOp Guru, Andy Lee, MD, and Elizabeth Fortin, MD, discuss visual snow syndrome and whether it should be evaluated during standard in-clinic ophthalmologic testing.
Read More
Florida appeals court reinstates lawsuit against ophthalmologist
September 24th 2022The Florida Second District Court of Appeal has renewed a woman’s lawsuit claiming she suffered permanent eye damage when her ophthalmologist misdiagnosed her during nasal surgery. In its opinion, the appellate court ruled that the trial court erred when it dismissed the lawsuit.
Read More
VIDEO: Drops for presbyopia correction show promise in Phase 3 safety studies
September 20th 2022At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.
Read More